Patients with EBV-positive tumors and high PD-L1 expression responded better to the therapy, especially those with NKTCL, while no response was observed for patients with relapsed/refractory EBV-negative NHL tumors in this cohort [95]. This evidence concerns the gene CD274 and extranodal nasal NK/T cell lymphoma.